- Home
- RNAZ vs RSLS Comparison
RNAZ vs RSLS Comparison
Compare RNAZ & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- RSLS
- Stock Information
- Founded
- RNAZ 2016
- RSLS 2002
- Country
- RNAZ United States
- RSLS United States
- Employees
- RNAZ N/A
- RSLS N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- RNAZ Health Care
- RSLS Health Care
- Exchange
- RNAZ Nasdaq
- RSLS Nasdaq
- Market Cap
- RNAZ 6.1M
- RSLS 5.7M
- IPO Year
- RNAZ 2021
- RSLS 2007
- Fundamental
- Price
- RNAZ $11.51
- RSLS $2.03
- Analyst Decision
- RNAZ Strong Buy
- RSLS
- Analyst Count
- RNAZ 1
- RSLS 0
- Target Price
- RNAZ $280.00
- RSLS N/A
- AVG Volume (30 Days)
- RNAZ 251.6K
- RSLS 487.2K
- Earning Date
- RNAZ 08-22-2025
- RSLS 08-22-2025
- Dividend Yield
- RNAZ N/A
- RSLS N/A
- EPS Growth
- RNAZ N/A
- RSLS N/A
- EPS
- RNAZ N/A
- RSLS N/A
- Revenue
- RNAZ N/A
- RSLS $7,175,000.00
- Revenue This Year
- RNAZ N/A
- RSLS $52.80
- Revenue Next Year
- RNAZ N/A
- RSLS N/A
- P/E Ratio
- RNAZ N/A
- RSLS N/A
- Revenue Growth
- RNAZ N/A
- RSLS N/A
- 52 Week Low
- RNAZ $6.15
- RSLS $1.87
- 52 Week High
- RNAZ $739.20
- RSLS $303.25
- Technical
- Relative Strength Index (RSI)
- RNAZ 56.95
- RSLS 38.23
- Support Level
- RNAZ $10.16
- RSLS $1.87
- Resistance Level
- RNAZ $12.10
- RSLS $2.85
- Average True Range (ATR)
- RNAZ 1.40
- RSLS 0.22
- MACD
- RNAZ -0.11
- RSLS -0.02
- Stochastic Oscillator
- RNAZ 23.51
- RSLS 9.88
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.